First patient dosed in Racura’s HARNESS-1 trial of RC220

Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing a combination of RC220 and osimertinib for EGFR-mutant NSCLC. The first patient was treated at Monash Health in Clayton, Victoria, Australia, with other trial sites planned in the near future. EGFR-mutant NSCLC represents a molecularly defined subtype often facing acquired resistance to therapies such as osimertinib. Credit: Saiful52 / Shutterstock.com. Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing RC220 in combination with osimertinib for epidermal growth factor receptor-mutant non-small cell lung cancer (EGFR-mutant NSCLC). The patient received RC220 at 50mg/m²…

Source: Clinical Trials Arena